Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab alone or with anti-LAG-3 and anti-TIM-3 in first-line PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
2021-005775-39Phase 2Active
- Sponsor
- Incyte
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Retifanlimab alone, Retifanlimab + INCAGN02385 and Retifanlimab + INCAGN02385 + INCAGN02390 (3 arms). Primary endpoint: Progression-free survival. Started May 2022; status: active.
02
Drugs
retifanlimabtuparstobartverzistobart
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2021-005775-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005775-39.